Zika Virus Disease Clinical Trial
Official title:
Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine
NCT number | NCT03158233 |
Other study ID # | VAG00001 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 29, 2017 |
Est. completion date | December 19, 2018 |
Verified date | April 2022 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This prospective, surveillance study will assess the operational Zika virus definition for use in future Zika purified inactivated virus (ZIKV) vaccine efficacy trials in order to identify Zika virus disease (ZVD) cases among the study cohort.
Status | Completed |
Enrollment | 2400 |
Est. completion date | December 19, 2018 |
Est. primary completion date | December 19, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years to 40 Years |
Eligibility | Inclusion Criteria: 1. Aged 15 to 40 years on the day of inclusion, currently residing in the site zone, and planning to continue to reside in the site zone for the duration of the study 2. For subjects under the age of majority on the day of inclusion: the assent form has been signed and dated by the subject (if required by local regulations), and the informed consent form has been signed and dated by the parent(s) or legal guardian(s). For subjects at or over the age of majority on the day of inclusion: the informed consent form has been signed and dated. 3) Subject (and parent/guardian if subject is under the age of majority) able to attend all scheduled visits and to comply with all study procedures 4) In good health, based on medical history and physical examination Exclusion Criteria: 1. Subject is pregnant (as self-reported) 2. Participation in the 4 weeks preceding enrollment, or planned participation during the present study period, in a clinical trial investigating a vaccine, drug, medical device, or a medical procedure 3. Receipt of any dengue or yellow fever vaccine in the 4 weeks preceding the day of enrollment or planned receipt of any dengue or yellow fever vaccine during the study period 4. Receipt of immune globulins, blood or blood-derived products in the past 3 months 5. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) 6. History of Zika virus disease, confirmed either clinically, serologically, or virologically 7. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion 8. Current alcohol abuse or drug addiction 9. Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily 10. Identified as an investigator or an employee of the investigator or study center, with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study. |
Country | Name | City | State |
---|---|---|---|
Colombia | Investigational Site | Cali | Valle Del Cauca |
Colombia | Investigational Site | Floridablanca | Santander |
Honduras | Investigational site | Tegucigalpa | |
Mexico | Investigational Site | Acapulco | Guerrero |
Mexico | Investigational Site | Temixco | Morelos |
Puerto Rico | Investigational Site | Carolina |
Lead Sponsor | Collaborator |
---|---|
Sanofi Pasteur, a Sanofi Company |
Colombia, Honduras, Mexico, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with suspected ZVD and virologically confirmed Zika (VCZ) infection in the cohort | Number of suspected ZVD and VCZ infections | Day 0 to Day 365 | |
Primary | Summary of the signs and symptoms accompanying suspected ZVD and VCZ cases in the study participants | Occurrence, intensity, and duration of signs and symptoms of ZVD and VCZ cases | Day 0 to Day 365 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03343626 -
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
|
Phase 1 | |
Completed |
NCT03624946 -
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
|
Phase 1 | |
Completed |
NCT02733796 -
Persistence of Zika Virus in Semen After Acute Infection
|